Acorda Therapeutics Inc (fka ACORQ)

[surf1944]

7:00AM Acorda Therapeutics presents preclinical data showing Dalfampridine improves motor function in chronic stroke (ACOR) 26.30 : Co presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event. Co plans to begin a proof-of-concept trial of AMPYRA in stroke by the end of 2012. Dalfampridine, also known as 4-aminopyridine, is the active chemical ingredient in AMPYRA Extended Release Tablets, 10 mg. AMPYRA is approved in the United States as a treatment to improve walking in patients with multiple sclerosis.